Massmutual Trust Co. FSB ADV Purchases 237 Shares of Moderna, Inc. (NASDAQ:MRNA)

Massmutual Trust Co. FSB ADV lifted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 71.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 571 shares of the company’s stock after acquiring an additional 237 shares during the period. Massmutual Trust Co. FSB ADV’s holdings in Moderna were worth $61,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. LPL Financial LLC raised its holdings in shares of Moderna by 7.2% during the third quarter. LPL Financial LLC now owns 115,782 shares of the company’s stock valued at $11,959,000 after purchasing an additional 7,811 shares during the last quarter. Mariner LLC lifted its holdings in shares of Moderna by 5.2% during the 3rd quarter. Mariner LLC now owns 20,242 shares of the company’s stock valued at $2,091,000 after buying an additional 996 shares during the period. Stifel Financial Corp boosted its stake in shares of Moderna by 19.0% in the 3rd quarter. Stifel Financial Corp now owns 75,871 shares of the company’s stock worth $7,837,000 after buying an additional 12,099 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Moderna by 1.9% in the third quarter. Northern Trust Corp now owns 2,971,056 shares of the company’s stock worth $306,880,000 after acquiring an additional 55,177 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. increased its position in Moderna by 12.2% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 3,610 shares of the company’s stock valued at $373,000 after acquiring an additional 393 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 1,296 shares of the stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $162.47, for a total value of $210,561.12. Following the sale, the insider now directly owns 10,623 shares of the company’s stock, valued at approximately $1,725,918.81. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Shannon Thyme Klinger sold 1,296 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $162.47, for a total value of $210,561.12. Following the completion of the transaction, the insider now directly owns 10,623 shares of the company’s stock, valued at $1,725,918.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the completion of the transaction, the president now owns 1,457,089 shares of the company’s stock, valued at approximately $201,311,416.24. The disclosure for this sale can be found here. Over the last three months, insiders sold 411,255 shares of company stock worth $55,846,531. Company insiders own 15.70% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Oppenheimer upped their price target on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th. Evercore ISI assumed coverage on shares of Moderna in a report on Tuesday, May 14th. They set an “in-line” rating and a $120.00 target price for the company. UBS Group lifted their price target on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Monday, June 3rd. Finally, Canaccord Genuity Group upped their price target on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a research report on Friday, May 3rd. Two analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus target price of $129.02.

Moderna Stock Performance

NASDAQ MRNA opened at $133.40 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The stock’s fifty day moving average is $131.68 and its two-hundred day moving average is $110.31. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $170.47.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. During the same quarter last year, the firm earned $0.19 earnings per share. The firm’s quarterly revenue was down 91.0% compared to the same quarter last year. Equities analysts forecast that Moderna, Inc. will post -7.46 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.